AGENUS INC (AGEN)

Insider Trading Filed: 2026-04-28

Key Insights

Director Susan Hirsch received a stock option grant of 105,000 shares at an exercise price of $3.90, vesting over one year from the April 24, 2026 grant date, indicating ongoing equity compensation for board members.
The option grant represents a standard director compensation practice under the 2019 Amended and Restated Equity Incentive Plan, suggesting routine governance and talent retention at the company.
This is a non-cash transaction with no immediate stock acquisition, so it does not signal insider confidence through personal capital deployment at current market prices.

Insider Trading Filed: 2026-04-28

Key Insights

Jennifer Buell, Chairman of the Executive Council, received a significant stock option grant of 305,000 shares total (300,000 + 5,000) at an exercise price of $3.90, granted on 04/24/2026 with a 10-year expiration.
The options vest over three years with one-third vesting on 04/24/2027 and the remaining balance in equal quarterly installments, indicating the company is using equity incentives for executive retention.
This is a compensation grant rather than an open market transaction, representing the company's confidence in future performance and executive commitment rather than a signal of insider buying pressure.

Insider Trading Filed: 2026-04-28

Key Insights

Chief Medical Officer Steven O'Day received 165,333 stock options total (70,000 + 95,333) with an exercise price of $3.90, indicating the company valued shares at this level on the grant date of April 24, 2026.
The 95,333 options granted in lieu of 2025 annual cash bonus vest immediately on May 24, 2026, suggesting the company may have prioritized equity compensation over cash, potentially indicating liquidity constraints or a strategic shift toward aligning executive interests with shareholder value.
Standard vesting schedule on the primary 70,000 option grant (one-third on April 24, 2027, then equal quarterly installments) demonstrates typical retention incentive structure for senior medical leadership over a three-year period.

Insider Trading Filed: 2026-04-28

Key Insights

Director Thomas Harrison received 122,500 stock options at an exercise price of $3.90 per share, vesting one year from the grant date (04/24/2027), representing standard equity compensation for board members.
The option grant occurred on 04/24/2026 and was filed four days later on 04/28/2026, following normal SEC filing procedures with no apparent delay or irregularity.
No corresponding sale or disposition of shares by Harrison is reported, suggesting this is a pure compensation event with no insider selling activity to analyze for sentiment signals.

Insider Trading Filed: 2026-04-28

Key Insights

Director Timothy Wright received a stock option grant of 105,000 shares at an exercise price of $3.90 per share, vesting one year from the April 24, 2026 grant date, indicating ongoing equity compensation for board-level participation.
The option grant represents a modest equity incentive with a relatively low strike price of $3.90, suggesting the company's stock was trading near or below this level at the time of grant.
This is a standard equity award under the company's 2019 Amended and Restated Equity Incentive Plan with typical one-year vesting, reflecting normal director compensation practices rather than a significant insider transaction signal.

Insider Trading Filed: 2026-04-28

Key Insights

Austin Charette, an officer at Agenus Inc., received 22,619 stock options total on April 24, 2026, demonstrating ongoing equity compensation to management but no direct stock purchases by insider.
The larger option grant of 17,619 shares was awarded in lieu of 2025 annual cash bonus and vests immediately on May 24, 2026, suggesting the company may be preserving cash while retaining key personnel through equity incentives.
The smaller option grant of 5,000 shares follows standard vesting over three years, indicating long-term retention strategy for this officer position at Agenus Inc.

Insider Trading Filed: 2026-04-28

Key Insights

CEO Armen Garo H received substantial equity compensation totaling 1,165,300 stock options with a $3.90 exercise price, indicating company confidence in future performance and aligning executive interests with shareholders.
The largest tranche of 1,000,000 options vests over three years starting April 2027, suggesting the company is incentivizing long-term retention and strategic execution rather than short-term gains.
137,550 options were awarded in lieu of 2025 annual cash bonus (vesting May 2026), indicating potential cash preservation strategy or shift toward equity-based compensation structure.
All options granted on 04/24/2026 with 10-year expiration demonstrate standard equity incentive plan practices aligned with the 2019 Amended and Restated Equity Incentive Plan framework.

Insider Trading Filed: 2026-04-28

Key Insights

Director Brian Corvese received a stock option grant of 210,000 shares at an exercise price of $3.90, vesting one year from the April 24, 2026 grant date, indicating continued compensation alignment with company performance.
The option grant represents a standard equity incentive under Agenus's 2019 Amended and Restated Equity Incentive Plan, suggesting routine director compensation rather than a special retention or performance-based award.
No common stock transactions are reported in this filing, indicating the director is not currently buying or selling shares on the open market, which could suggest either confidence in holding existing positions or a blackout/trading restriction period.

Insider Trading Filed: 2026-04-21

Key Insights

CEO Garo H. Armen acquired 3,403 shares at $4.79 per share through salary conversion to equity, indicating a voluntary alignment of his compensation with shareholder interests rather than selling pressure.
The filing reveals total beneficial ownership of approximately 402,798 shares (direct and indirect combined), with significant indirect holdings through IRA accounts (31,298 shares) and partnership interests (28,950 shares), demonstrating substantial personal stake in the company.
The salary-paid-in-stock arrangement approved by the Compensation Committee suggests potential cash preservation strategy or confidence in future stock performance, as the CEO voluntarily accepts equity compensation rather than cash.
All acquired shares are fully vested upon issuance and represent routine compensation activity rather than open market purchases, which limits the signal strength typically associated with insider buying patterns.

Insider Trading Filed: 2026-04-13

Key Insights

Insider Thomas L. Harrison, a director at Agenus Inc. (AGEN), acquired 9,228 shares of the company's common stock at an average price of $3.319 per share.
This transaction increased Harrison's direct beneficial ownership in Agenus to 38,998 shares, indicating his continued confidence in the company.
The share acquisition was made under the Agenus Inc. Board Compensation Election Policy, which allows directors to receive their fees in the form of company stock.

Insider Trading Filed: 2026-04-06

Key Insights

Garo H. Armen, the Chairman and CEO of Agenus Inc., acquired 4,629 shares of the company's common stock at $3.33 per share as part of his salary compensation.
Armen also holds an additional 31,298 shares indirectly through his IRA accounts and 28,950 shares through a trust he controls, indicating his significant ownership stake in the company.
The company's SEC Form 4 filing suggests Armen's alignment with shareholders and confidence in Agenus' future prospects.

Current Report Filed: 2026-03-26

Key Insights

The U.S. District Court for the District of Massachusetts granted Agenus Inc. and its executives' motion to dismiss a putative securities class action lawsuit in its entirety.
The court ruled in favor of Agenus Inc. and its executives, Garo H. Armen, Christine M. Klaskin, Steven J. O'Day, and Todd Yancey, denying the plaintiff's request for leave to amend.
This dismissal of the lawsuit against Agenus Inc. and its executives removes a legal overhang and potential financial liability, which could be viewed positively by investors.

Insider Trading Filed: 2026-03-24

Key Insights

Garo H. Armen, the Chairman and CEO of Agenus Inc., has acquired additional shares of the company's common stock as part of his salary compensation, indicating his confidence in the company's future.
Armen's shares are held both directly and indirectly through his IRA accounts and a family trust, suggesting a long-term investment strategy.
The company's compensation structure, which allows the CEO to receive a portion of his salary in stock, aligns his interests with those of other shareholders.

Insider Trading Filed: 2026-03-09

Key Insights

Agenus Inc. CEO Garo H. Armen has received 4,994 shares of common stock as part of his salary, indicating alignment with shareholders through equity-based compensation.
Armen holds a significant direct ownership stake of 330,535 shares in Agenus, as well as indirect ownership through his IRA accounts and a trust, suggesting strong management commitment.
The company's decision to pay the CEO's salary in stock rather than cash may signal financial discipline and a focus on preserving cash during the current period.

Insider Trading Filed: 2026-02-09

Key Insights

The CEO, Garo H. Armen, acquired 5,027 shares of Agenus Inc. common stock as part of his compensation, indicating his continued commitment to the company.
Armen also holds a significant amount of Agenus stock indirectly through his IRA accounts and a family trust, suggesting he has a substantial personal stake in the company's success.
The stock acquisition was made at a price of $2.94 per share, which appears to be the market price at the time of the transaction.

Insider Trading Filed: 2026-01-26

Key Insights

Garo H. Armen, the Chairman and CEO of Agenus Inc., has received shares of the company's common stock as part of his salary compensation instead of cash.
Armen holds a significant amount of Agenus shares, both directly and indirectly through his IRA accounts and a grantor retained annuity trust (GRAT) that he controls.
The reported transaction involves the acquisition of 4,562 shares of Agenus common stock at a price of $3.24 per share, which represents Armen's salary for the pay period ending January 23, 2026.

Current Report Filed: 2026-01-16

Key Insights

Agenus has completed the sale of its manufacturing operations to Zydus Pharmaceuticals for $75 million, which represents a significant divestment of assets for the company.
In connection with the asset sale, Agenus has entered into an exclusive license agreement with Zydus to develop, manufacture, and commercialize its proprietary BOT/BAL cancer immunotherapy drug product in Sri Lanka and India.
Agenus has also raised $16 million through the issuance of 2,133,333 shares of common stock to Zynext Ventures, a subsidiary of Zydus Lifesciences Limited, as part of the overall transaction.

Current Report Filed: 2026-01-14

Key Insights

Agenus has appointed its current Chairman and CEO, Dr. Garo Armen, as the interim Chief Financial Officer and Principal Financial Officer, indicating a need for senior leadership oversight in the finance function.
The company has also appointed Austin Charette, the current Senior Director of Financial Reporting and Compliance, as the new Principal Accounting Officer, providing continuity and experience in the accounting function.
The leadership changes do not appear to be accompanied by any new compensation arrangements or modifications to existing ones, suggesting a more transitional nature of the appointments.

Insider Trading Filed: 2026-01-12

Key Insights

Garo H. Armen, the Chairman and CEO of Agenus Inc., has been compensated in the form of company stock instead of cash, indicating potential confidence in the company's future.
Armen holds a significant amount of Agenus stock, both directly and indirectly through his IRA accounts and a trust, suggesting his alignment with shareholders.
The recent stock acquisition of 3,780 shares at $3.91 per share represents a relatively small transaction, but it may signal Armen's ongoing commitment to the company.

Current Report Filed: 2026-01-08

Key Insights

Agenus Inc. has entered into an amendment and release agreement with Ligand Pharmaceuticals Incorporated, which modifies the exercise price under a previously disclosed warrant from $17.30 per share to $7.50 per share.
The amendment agreement provides for a release by Ligand of liens it has on certain of Agenus' assets in exchange for the warrant exercise price reduction.
This agreement may provide Agenus with improved financial flexibility and access to capital, which could be beneficial for the company's operations and growth.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information